Two cases of eczematous eruptions caused by everolimus

Everolimus, an inhibitor of the mammalian target of rapamycin, has been used in the treatment of several types of tumor. Erythematous maculopapular and acneiform rashes are the major dermatological adverse events associated with everolimus therapy, but we encountered two cases of eczematous eruption caused by everolimus.

[1]  J. Hao,et al.  RAD001 (everolimus) attenuates experimental autoimmune neuritis by inhibiting the mTOR pathway, elevating Akt activity and polarizing M2 macrophages , 2016, Experimental Neurology.

[2]  A. Heiligenhaus,et al.  Everolimus improves experimental autoimmune uveoretinitis. , 2012, Experimental eye research.

[3]  R. Motzer,et al.  Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors , 2012, Cancer.

[4]  M. Lacouture,et al.  Eosinophilic rash secondary to temsirolimus. , 2009, Clinical genitourinary cancer.

[5]  F. Giles,et al.  The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents , 2009, Targeted Oncology.

[6]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[7]  T. Mizushima,et al.  Therapeutic effect of a new immunosuppressive agent, everolimus, on interleukin‐10 gene‐deficient mice with colitis , 2007, Clinical and experimental immunology.

[8]  C. Bodemer,et al.  Cutaneous Adverse Events in Renal Transplant Recipients Receiving Sirolimus-Based Therapy1 , 2005, Transplantation.

[9]  E. Raymond,et al.  Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Koichiro Nakamura,et al.  Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity. , 2001, The Journal of allergy and clinical immunology.